Cargando…

Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial

BACKGROUND: Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. OBJECTIVE: To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. ANIMALS: Forty‐nine client‐owned dogs with CKD. METHODS: Dogs were randomized to ben...

Descripción completa

Detalles Bibliográficos
Autores principales: King, J.N., Font, A., Rousselot, J.‐F., Ash, R.A., Bonfanti, U., Brovida, C., Crowe, I.D., Lanore, D., Pechereau, D., Seewald, W., Strehlau, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508345/
https://www.ncbi.nlm.nih.gov/pubmed/28669137
http://dx.doi.org/10.1111/jvim.14726
_version_ 1783249862447333376
author King, J.N.
Font, A.
Rousselot, J.‐F.
Ash, R.A.
Bonfanti, U.
Brovida, C.
Crowe, I.D.
Lanore, D.
Pechereau, D.
Seewald, W.
Strehlau, G.
author_facet King, J.N.
Font, A.
Rousselot, J.‐F.
Ash, R.A.
Bonfanti, U.
Brovida, C.
Crowe, I.D.
Lanore, D.
Pechereau, D.
Seewald, W.
Strehlau, G.
author_sort King, J.N.
collection PubMed
description BACKGROUND: Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. OBJECTIVE: To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. ANIMALS: Forty‐nine client‐owned dogs with CKD. METHODS: Dogs were randomized to benazepril (0.25 to <0.5 mg/kg) or placebo once daily for up to 2 years in a prospective, multicenter, blinded clinical trial. The primary endpoint variable was the renal survival time, defined as the time from inclusion in the study to the treatment failure endpoint of death or euthanasia or need for administration of parenteral fluids related to renal failure. RESULTS: No benefit of benazepril versus placebo was detected for renal survival time in all dogs; median (95% confidence interval (CI)) survival times were 305 (53–575) days in the benazepril group and 287 (152‐not available) in the placebo group (P = .53). Renal survival times were not significantly longer with benazepril compared to placebo for subgroups: hazard ratios (95% CI) were 0.50 (0.21–1.22) with P = .12 for initial urine protein‐to‐creatinine ratio (UPC) >0.5, and 0.38 (0.12–1.19) with P = .080 for initial UPC >0.5 plus plasma creatinine ≤440 μmol/L. Proteinuria, assessed from the UPC, was significantly (P = .0032) lower after treatment with benazepril compared to placebo. There were no significant differences between groups for clinical signs or frequencies of adverse events. CONCLUSIONS AND CLINICAL RELEVANCE: Benazepril significantly reduced proteinuria in dogs with CKD. Insufficient numbers of dogs were recruited to allow conclusions on survival time.
format Online
Article
Text
id pubmed-5508345
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55083452017-07-14 Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial King, J.N. Font, A. Rousselot, J.‐F. Ash, R.A. Bonfanti, U. Brovida, C. Crowe, I.D. Lanore, D. Pechereau, D. Seewald, W. Strehlau, G. J Vet Intern Med SMALL ANIMAL BACKGROUND: Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. OBJECTIVE: To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. ANIMALS: Forty‐nine client‐owned dogs with CKD. METHODS: Dogs were randomized to benazepril (0.25 to <0.5 mg/kg) or placebo once daily for up to 2 years in a prospective, multicenter, blinded clinical trial. The primary endpoint variable was the renal survival time, defined as the time from inclusion in the study to the treatment failure endpoint of death or euthanasia or need for administration of parenteral fluids related to renal failure. RESULTS: No benefit of benazepril versus placebo was detected for renal survival time in all dogs; median (95% confidence interval (CI)) survival times were 305 (53–575) days in the benazepril group and 287 (152‐not available) in the placebo group (P = .53). Renal survival times were not significantly longer with benazepril compared to placebo for subgroups: hazard ratios (95% CI) were 0.50 (0.21–1.22) with P = .12 for initial urine protein‐to‐creatinine ratio (UPC) >0.5, and 0.38 (0.12–1.19) with P = .080 for initial UPC >0.5 plus plasma creatinine ≤440 μmol/L. Proteinuria, assessed from the UPC, was significantly (P = .0032) lower after treatment with benazepril compared to placebo. There were no significant differences between groups for clinical signs or frequencies of adverse events. CONCLUSIONS AND CLINICAL RELEVANCE: Benazepril significantly reduced proteinuria in dogs with CKD. Insufficient numbers of dogs were recruited to allow conclusions on survival time. John Wiley and Sons Inc. 2017-07-01 2017 /pmc/articles/PMC5508345/ /pubmed/28669137 http://dx.doi.org/10.1111/jvim.14726 Text en Copyright © 2017 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle SMALL ANIMAL
King, J.N.
Font, A.
Rousselot, J.‐F.
Ash, R.A.
Bonfanti, U.
Brovida, C.
Crowe, I.D.
Lanore, D.
Pechereau, D.
Seewald, W.
Strehlau, G.
Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial
title Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial
title_full Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial
title_fullStr Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial
title_full_unstemmed Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial
title_short Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial
title_sort effects of benazepril on survival of dogs with chronic kidney disease: a multicenter, randomized, blinded, placebo‐controlled clinical trial
topic SMALL ANIMAL
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508345/
https://www.ncbi.nlm.nih.gov/pubmed/28669137
http://dx.doi.org/10.1111/jvim.14726
work_keys_str_mv AT kingjn effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT fonta effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT rousselotjf effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT ashra effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT bonfantiu effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT brovidac effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT croweid effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT lanored effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT pechereaud effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT seewaldw effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial
AT strehlaug effectsofbenazeprilonsurvivalofdogswithchronickidneydiseaseamulticenterrandomizedblindedplacebocontrolledclinicaltrial